A retrospective study of the association between megestrol acetate administration and mortality among nursing home residents with clinically significant weight loss

American Journal Geriatric Pharmacotherapy

Volumn 5, Issue 2, 2007, Pages 137-146

  Bodenner, Donald ^a,b,c   Spencer, Trey ^d   Riggs, Ann T ^a   Redman, Carolyn ^a   Strunk, Billy ^e   Hughes, Tony ^e  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e Beverly Enterprises   (United States)

Author keywords

aged; elderly; megestrol acetate; nursing home

Indexed keywords

MEGESTROL ACETATE;

AGED; ARTICLE; BODY WEIGHT; CANCER; CASE CONTROL STUDY; COGNITION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEATH; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; ELDERLY CARE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NURSING HOME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; UNITED STATES; WASTING SYNDROME; WEIGHT GAIN; WEIGHT REDUCTION;

AGED; ANOREXIA; APPETITE STIMULANTS; CACHEXIA; FEMALE; HUMANS; MALE; MEGESTROL ACETATE; NURSING HOMES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UNITED STATES; WEIGHT LOSS;

EID: 34547962850     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2007.06.004     Document Type: Article

References (55)

1. Liu L., Bopp M., Roberson P., and Sullivan D. Undernutrition and risk of mortality in elderly patients within 1 year of hospital discharge. J Gerontol A Biol Sci Med Sci 57 (2002) M741-M746
2. Ostergaard E. The oral progestational and anti-ovulatory properties of megestrol acetate and its therapeutic use in gynaecological disorders. J Obstet Gynaecol Br Emp 72 (1965) 45-48
3. Elstein M. Low-dose progestagens as contraceptive agents. IPPF Med Bull 4 (1970) 2-4
4. Megace oral suspension for anorexia and cachexia in AIDS. Adv Nurse Pract 5 (1997) 67
5. Bell S., Hestnes J., Wanke C., and Forse R. Megestrol acetate in patients with AIDS-related cachexia. JPEN J Parenter Enteral Nutr 20 (1996) 165-166
6. Brady M., Koranyi K., and Hunkler J. Megestrol acetate for treatment of anorexia associated with human immunodeficiency virus infection in children. Pediatr Infect Dis J 13 (1994) 754-756
7. Strang P. The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Anticancer Res 17 (1997) 657-662
8. Furth P. Megestrol acetate and cachexia associated with human immunodeficiency virus (HIV) infection. Ann Intern Med 110 (1989) 667-668
9. Schmoll E., Wilke H., Thole R., et al. Megestrol acetate in cancer cachexia. Semin Oncol 18 Suppl 2 (1991) 32-34
10. McMillan D., Wigmore S., Fearon K., et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 79 (1999) 495-500
11. Heckmayr M., and Gatzemeier U. Megestrol acetate in cachectic patients with advanced bronchogenic cancer. Onkologie 13 (1990) 285-287
12. Fietkau R., Riepl M., Kettner H., et al. Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. Eur J Cancer 33 (1997) 75-79
13. De Conno F., Martini C., Zecca E., et al. Megestrol acetate for anorexia in patients with far-advanced cancer: A double-blind controlled clinical trial. Eur J Cancer 34 (1998) 1705-1709
14. Azcona C., Castro L., Crespo E., et al. Megestrol acetate therapy for anorexia and weight loss in children with malignant solid tumours. Aliment Pharmacol Ther 10 (1996) 577-586
15. Vadell C., Segui M., Gimenez-Arnau J., et al. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol 21 (1998) 347-351
16. AHFS 2007 Drug Information (2007), American Society of Health-System Pharmacists, Inc, Bethesda, Md 1123
17. Lee L., and Glenn M. Adrenal insufficiency masquerading as sepsis in a patient with tetraparesis: A case report. Arch Phys Med Rehabil 81 (2000) 830-833
18. Eubanks V., Koppersmith N., Wooldridge N., et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. J Pediatr 140 (2002) 439-444
19. Leinung M., Liporace R., and Miller C. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 122 (1995) 843-845
20. Marchand V., Baker S., Stark T., and Baker R. Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. J Pediatr Gastroenterol Nutr 31 (2000) 264-269
21. Naing K., Dewar J., and Leese G. Megestrol acetate therapy and secondary adrenal suppression. Cancer 86 (1999) 1044-1049
22. Ron I., Soyfer V., Goldray D., et al. A low-dose adreno-corticotropin test reveals impaired adrenal function in cancer patients receiving megestrol acetate therapy. Eur J Cancer 38 (2002) 1490-1494
23. Stockheim J., Daaboul J., Yogev R., et al. Adrenal suppression in children with the human immunodeficiency virus treated with megestrol acetate. J Pediatr 134 (1999) 368-370
24. Stoffer S., and Krakauer J. Induction of adrenal suppression by megestrol acetate. Ann Intern Med 124 (1996) 613-614
25. Subramanian S., Goker H., Kanji A., and Sweeney H. Clinical adrenal insufficiency in patients receiving megestrol therapy. Arch Intern Med 157 (1997) 1008-1011
26. Alexieva-Figusch J., Blankenstein M., Hop W., et al. Treatment of metastatic breast cancer patients with different dosages of megestrol acetate: Dose relations, metabolic and endocrine effects. Eur J Cancer Clin Oncol 20 (1984) 33-40
27. Mann M., Koller E., Murgo A., et al. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 157 (1997) 1651-1656
28. Middleton D., Watson A., Howe C., and Caterson I. Suppression of cortisol responses to exogenous adreno-corticotrophic hormone, and the occurrence of side effects attributable to glucocorticoid excess, in cats during therapy with megestrol acetate and prednisolone. Can J Vet Res 51 (1987) 60-65
29. Loprinzi C., Schaid D., Dose A., et al. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 11 (1993) 152-154
30. Kropsky B., Shi Y., and Cherniack E. Incidence of deep-venous thrombosis in nursing home residents using megestrol acetate. J Am Med Dir Assoc 4 (2003) 255-256
31. author reply 881. Hengge U., Brockmeyer N., and Goos M. Megestrol for AIDS-related anorexia. Ann Intern Med 122 (1995) 879
32. Loprinzi C., Fonseca R., and Jensen M. Megestrol acetate-induced adrenal suppression. J Clin Oncol 14 (1996) 689
33. Karcic E., Philpot C., and Morley J. Treating malnutrition with megestrol acetate: Literature review and review of our experience. J Nutr Health Aging 6 (2002) 191-200
34. Castle S., Nguyen C., Joaquin A., et al. Megestrol acetate suspension therapy in the treatment of geriatric anorexia/cachexia in nursing home patients. J Am Geriatr Soc 43 (1995) 835-836
35. Rosenbaum P. Optimal matching for observational studies. J Am Stat Assoc 84 (1989) 1024-1032
36. Bergstralh E., and Kosanke J. Computerized matching of cases to controls. Mayo Foundation Technical Report Series 56 (1995)
37. Lundgren S., Helle S., and Lonning P. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clin Cancer Res 2 (1996) 1515-1521
38. Pinelli D., Fiorica J., Roberts W., et al. Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: A phase II study. Gynecol Oncol 60 (1996) 462-467
39. Stuart N., Warwick J., Blackledge G., et al. A randomised phase II cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Eur J Cancer 32A (1996) 1888-1892
40. Donald S. Megestrol acetate and appetite gain. Vet Rec 101 (1977) 472
41. Chao Y., Chan W., Wang S., et al. Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 12 (1997) 277-281
42. Yeh S., Wu S., Lee T., et al. Improvement in quality-of-life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: Results of a double-blind, placebo-controlled study. J Am Geriatr Soc 48 (2000) 485-492
43. Reuben D., Hirsch S., Zhou K., and Greendale G. The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: A phase II randomized clinical trial. J Am Geriatr Soc 53 (2005) 970-975
44. Simmons S., Walker K., and Osterweil D. The effect of megestrol acetate on oral food and fluid intake in nursing home residents: A pilot study. J Am Med Dir Assoc 6 Suppl 3 (2005) S5-S11
45. Lambert C., Sullivan D., Freeling S., et al. Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: A randomized controlled trial. J Clin Endocrinol Metab 87 (2002) 2100-2106
46. Terada K., Suthum P., Katsura K., and Hokama Y. The effect of megestrol acetate on interleukin-1 activity. Gynecol Oncol 43 (1991) 260-261
47. Mantovani G., Maccio A., Lai P., et al. Cytokine involvement in cancer anorexia/cachexia: Role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncog 9 (1998) 99-106
48. Yeh S., Wu S., Levine D., et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. J Gerontol A Biol Sci Med Sci 56 (2001) M48-M54
49. Jatoi A., Yamashita J., Sloan J., et al. Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. Support Care Cancer 10 (2002) 71-75
50. Loprinzi C., Jensen M., Jiang N., and Schaid D. Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clin Proc 67 (1992) 1160-1162
51. Yeh S., Hafner A., Chang C., et al. Risk factors relating blood markers of inflammation and nutritional status to survival in cachectic geriatric patients in a randomized clinical trial. J Am Geriatr Soc 52 (2004) 1708-1712
52. Simmons S., Garcia E., Cadogan M., et al. The minimum data set weight-loss quality indicator: Does it reflect differences in care processes related to weight loss?. J Am Geriatr Soc 51 (2003) 1410-1418
53. Lapane K., and Resnik L. Obesity in nursing homes: An escalating problem. J Am Geriatr Soc 53 (2005) 1386-1391
54. Girman C., Chandler J., Zimmerman S., et al. Prediction of fracture in nursing home residents. J Am Geriatr Soc 50 (2002) 1341-1347
55. Porock D., Oliver D., Zweig S., et al. Predicting death in the nursing home: Development and validation of the 6-month Minimum Data Set mortality risk index. J Gerontol A Biol Sci Med Sci 60 (2005) 491-498